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Abstract
Protein tyrosine phosphatase non-receptor type 22 (PTPN22) is a negative regulator of T-cell activation associated
with several autoimmune diseases, including systemic lupus erythematosus (SLE). Missense rs2476601 is
associated with SLE in individuals with European ancestry. Since the rs2476601 risk allele frequency differs
dramatically across ethnicities, we assessed robustness of PTPN22 association with SLE and its clinical sub-
phenotypes across four ethnically diverse populations. Ten SNPs were genotyped in 8220 SLE cases and 7369
controls from in European-Americans (EA), African-Americans (AA), Asians (AS), and Hispanics (HS). We performed
imputation-based association followed by conditional analysis to identify independent associations. Significantly
associated SNPs were tested for association with SLE clinical sub-phenotypes, including autoantibody profiles.
Multiple testing was accounted for by using false discovery rate. We successfully imputed and tested allelic
association for 107 SNPs within the PTPN22 region and detected evidence of ethnic-specific associations from EA
and HS. In EA, the strongest association was at rs2476601 (P = 4.761029, OR = 1.40 (95% CI = 1.25–1.56)).
Independent association with rs1217414 was also observed in EA, and both SNPs are correlated with increased
European ancestry. For HS imputed intronic SNP, rs3765598, predicted to be a cis-eQTL, was associated
(P = 0.007, OR = 0.79 and 95% CI = 0.67–0.94). No significant associations were observed in AA or AS. Case-only
analysis using lupus-related clinical criteria revealed differences between EA SLE patients positive for moderate to
high titers of IgG anti-cardiolipin (aCL IgG .20) versus negative aCL IgG at rs2476601 (P = 0.012, OR = 1.65).
Association was reinforced when these cases were compared to controls (P = 2.761025, OR = 2.11). Our results
validate that rs2476601 is the most significantly associated SNP in individuals with European ancestry.
Additionally, rs1217414 and rs3765598 may be associated with SLE. Further studies are required to confirm the
involvement of rs2476601 with aCL IgG.
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Introduction
Protein tyrosine phosphatase non-receptor type 22 (PTPN22) is
a powerful negative regulator of T-cell activation. This gene is strongly
associated with systemic lupus erythematosus (SLE) [1,2,3] as well as
other autoimmune diseases including type 1 diabetes [4], rheumatoid
arthritis [5], juvenile idiopathic arthritis [6], autoimmune thyroid
disease [7], granulomatosis with polyangiitis (formerly known as
Wegener’s granulomatosis) [8], myasthenia Gravis [9], Hashimotos
thyroiditis [10], Graves’ disease [11], Addison’s disease [12], systemic
sclerosis [13], and generalized vitiligo [14]. PTPN22 has strong
functional consequences for immune responses, supporting evidence
of association with SLE and other autoimmune diseases
[4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27].
PTPN22 is located on chromosome 1 and codes for the
lymphoid specific tyrosine phosphatase protein, Lyp. This
protein is comprised of 807 amino acids, and contains an N-
terminal protein tyrosine phosphatase (PTP) domain and four
proline-rich motifs (P1–4) in the C-terminal region. Lyp has a
major role in regulation of the Src family of tyrosine kinases
(SFKs). SFKs serve as molecular switches that regulate a variety
of cellular events including cell growth, division, differentiation
and programmed death. The P1 proline-rich motif of Lyp is
important for its interaction with the C-terminal Src tyrosine
kinase (CSK), a negative regulatory kinase [28]. Csk phosphor-
ylates C-terminal tyrosines in SFKs, and the Lyp-CSK
interaction destabilizes the kinase domains of SFKs through
tyrosine dephosphorylation. The well established PTPN22
polymorphism (rs2476601) encodes the amino acid substitution
of arginine to tryptophan at position 620 (R620W) which
disrupts the Lyp-Csk interaction and therefore has been the
main focus of many research studies [26].
SLE prevalence varies substantially by ethnic ancestry: African-
Americans have a 3 to 5 fold increased risk of SLE compared to
individuals with European ancestry [29,30,31]. Earlier studies
report association between PTPN22 and SLE, primarily with the
non-synonymous variant rs2476601 in European-derived popula-
tions. However, the frequency of this disease-associated SNPs
varies strongly among Europeans based on geographic region,
with a higher prevalence in Northern European countries relative
to Southern European populations [32,33]. Additionally,
rs2476601 is either monomorphic or extremely rare in the
Japanese population and only rarely observed among the admixed
African-American population [32].
In this study we investigated association PTPN22 variants in
SLE cases and healthy controls in four diverse ethnic populations
in order to elucidate the population specific relationship between
different PTPN22 SNPs and disease risk. Genetic associations were
examined in European-Americans (EA), African-Americans (AA),
Asians (AS), and Hispanics (HS). Our results confirm SLE
association with missense rs2476601 in EA, and we identified
association of rs3765598 with SLE in HS. No significant
associations were observed in AA or AS.
Materials and Methods
Ethics statement
Samples were supplied from multiple investigators from
different institutions with approval from their respective institu-
tional review boards (IRBs). All study participants provided written
consent prior to study enrolment; consent forms were obtained at
each location under IRB guidelines. Samples were then assembled
at the Oklahoma Medical Research Foundation (OMRF) and the
study protocols (including the enrollment process, consent forms,
collection of DNA and subject information) for this study were
approved by the Oklahoma Medical Research Foundation
(OMRF) Institutional Review Board.
Recruitment and Biological Sample Collection
We participated in the ‘‘Large Lupus Association Study #2’’
(LLAS2) in which .16,500 individuals were genotyped,
including 8068 EA, 3462 AA, 2509 HS, and 2672 AS. Details
of genotyping procedures have been described elsewhere [34].
All SLE cases met 1997 ACR classification criteria for SLE
[35,36]. Individual ethnicities were self-reported and genetic
outliers were removed by principal component analysis
(described below).
Genotyping
All genotype data were generated using Illumina iSelect at the
Oklahoma Medical Research Foundation (OMRF) genotyping
facility. For this project, ten PTPN22 SNPs were generated using
Illumina Genome Studio (http://www.illumina.com/software/
genomestudio_software.ilmn). Following genotype scoring, SNP
clusters were evaluated electronically using the Illumina BEAD-
STUDIOH software package (http://www.illumina.com). Ambig-
uous SNP clusters were evaluated manually and SNPs with poor
cluster characteristics were not analyzed. All samples had 350
AIMs (ancestry informative markers) and .6000 ‘‘null’’ SNPs (not
selected based on P-values, or known associated with any
autoimmune disease, http//www.gwascentral.org [37]) genotyped
to facilitate adjustment for genetic ancestry and population sub-
structure.
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Quality Control
Quality control (QC) of the genotype data was performed
before imputation. Subjects were excluded from analysis if they
had ,90% genotyping success or were population stratification
outliers. Samples were evaluated for relatedness using identity by
descent (IBD), and duplicate or related samples (IBD .0.25) were
removed. Using AIMs and ‘‘null’’ SNPs, we performed principal
component analysis (PCA, EIGENSTRAT [38,39], and STRUC-
TURE [40] to identify outliers, hidden population structure, and
estimate individual ancestry proportions as previously described
[41]. SNPs were removed if they had (a) .10% missing genotypes,
(b) showed evidence of deviation from Hardy-Weinberg equilib-
rium (PHWE,0.001 in controls or ,0.0001 in cases), (c) for poor
clustering, or had a minor allele frequency (MAF) ,1%.
Imputation-based Association Analysis
Imputation is a statistical method used to determine probabi-
listically missing or untyped genotypes using a densely mapped
reference panel (26–28). We performed imputation-based analysis
in our ethnic-specific case-control samples using publicly available
1000Genomes as data reference panels (2010–11 1000G Interim
Phase I) for imputation, including 246 AA (YRI+LWK+ASW),
381 EA (GBR+FIN+IBS+CEU+TSI), 181 HS (PUR+CLM+
MXL), and 286 AS (JPT+CHB+CHS). For HapMap family data
only founders were included in the reference panels. From this
region (114,356,663–114,418,205 bp) 527 SNPs were available.
Imputation was performed using MACH [42], which provided a
quantitative assessment of estimate uncertainty (Rsq). Allelic
association results were adjusting for imputation uncertainty with
mach2dat. All imputed SNPs were filtered based on QC measures
(HWE .0.001, MAF .0.01, Rsq .0.6).
Statistical Analyses for Assessing Genetic Association
At each SNP allelic association was assessed between cases and
control using the x2 test with 1 d.f. Allelic odds ratio (OR) and
95% confidence intervals (95% CIs) were calculated using PLINK
[43]. Haploview [44] was used to estimate the linkage disequilib-
rium (LD) between markers in each ethnic population. We
performed pair-wise conditional haplotype analysis using WHAP
[45] to identify which associations were independent, and not due
to LD with primarily associated SNPs. For each SNP we assessed
whether it was still associated with SLE after conditioning on the
most significant SNP. To correct for multiple testing, false
discovery rate (FDR) methods were used and q values were
calculated using PLINK (43). Q values correspond to the
proportion of false positives among the results. Thus, q values
,0.05 signify less than a 5% false positive rate and are taken as a
measure of significance.
ACR Classification Criteria and Sub-criteria Used for
Association Analysis
Clinical data for the ACR classification criteria [36] for each
participant was obtained through medical record review. ANA,
anti-dsDNA, anti-Sm, anti-cardiolipin were determined in the
CAP-certified OMRF Clinical Immunology Laboratory by an
immunofluorescence (ANA, anti-dsDNA), immunodiffusion (anti-
SM), or enzyme linked immunosorbent assay (aCL) at the
enrollment time point [46]. Individual ACR criterion, or sub-
criterion, including autoantibody status, were coded as positive,
negative, or missing. SLE patients were grouped by the presence
or absence of individual ACR criterion. Logistic regression and
Pearson x2 tests were used to assess statistical significance with
associated SNPs in both case-only (all cases positive for given
criteria versus all cases negative for the same criterion) and case-
control (all cases positive for given criterion versus all healthy
controls) analyses.
Results
A total of 7427 EA (3936 cases and 3491 controls), 3338 AA
(1527 cases and 1811 controls), 2525 AS (1265 cases and 1260
controls), and 2299 HS (1492 cases and 807 controls) passed QC
and were used for association analyses. All ten genotyped SNPs
passed QC in EA and HS, though rs2476601 was monomorphic
in AS and AA, and rs33996649 failed genotyping in AA and AS.
Using our genotypes and 1000Genomes Project data, 109 to 165
SNPs were imputed (165 in AA, 113 in EA, 109 in HS, and 101 in
AS). Of these, a total of 107 SNPs passed QC (81 in AA, 83 in EA,
83 HS, and 79 AS).
Significant allelic association between PTPN22 was observed in
EA and HS (Table 1). In EA, 46 SNPs were associated (p,0.05)
with SLE. The most significant association was with rs2476601
(P = 4.1361029, OR = 1.40 95% CI = 1.25–1.56) in EA. Intronic
SNP rs1217414 was also significant in EA (P = 7.3961024,
OR = 0.88 95% CI 0.82–0.95). Figure 1 shows the overall
haplotype structure from select SNPs in this genomic region in EA
including the two isoforms of PTPN22. All imputed SNPs from the
PTPN22 region are shown in Figure S1. SNP rs2476601 was not
significantly associated with SLE in HS (P = 0.20) and was
monomorphic in AA and AS.
In HS, 17 SNPs were significantly associated with SLE, all of
which were of similar magnitude (P-values between 0.003–0.007,
ORs between 0.79–0.82). Of these SNPs, rs3765598 (P = 0.007,
OR = 0.79 95% CI = 0.67–0.94) was predicted to be an eQTL
[47], which most likely affects binding and expression of PTPN22
in monocyte cell line [47].
To identify independent associations within significant signals in
EA, we performed conditional haplotype analysis using WHAP
[45]. This analysis showed that controlling for rs2476601
accounted for most of the association between PTPN22 and SLE
in EA (Table S1). However, since rs1217414 remained significant
after being conditioned on rs2476601 (P = 0.022), and rs2476601
remained significant (P = 7.061027) after conditioned on
rs1217414, we performed haplotype analysis using these SNPs.
The overall haplotype was significant (Phap = 2.40610
29) at a
similar magnitude as individual SNP rs2476601 (P = 4.1361029).
In fact, these SNPs are physically 35.6 kb apart and have a very
low LD (r2 = 0.04), implying independence. The risk haplotype at
both SNPs (AG) was the most significant (P = 9.5861029,
OR = 1.38), and the non-risk haplotype (GA) was significant as
well (P = 7.3961024, OR = 0.88). The haplotype which was non-
risk for rs2476601/risk for rs1217414 was not significant (GG)
(P = 0.63). When we compared the AG (both risk alleles) vs. GA
(both non-risk alleles), the OR increased to 1.47 (p = 9.561029).
However, we did not observe the (AA) haplotype in our data.
To assess whether PTPN22 genetic associations were enriched
in SLE patients with specific clinical manifestations, a case-only
analysis of the 11 ACR classification criteria and 5 autoantibodies
was performed. Case-only analysis demonstrated association
between rs2476601 and anticardiolipin IgG (aCL IgG .20)
antibody using 121 patients positive compared to 578 SLE patients
known to be negative for aCL IgG (P = 0.012, OR = 1.65
(95%CI = 1.11–2.46)) (Table 2). When adjusting for false
discovery rate (FDR) this association remained significant, though
the association was modest (FDR = 0.049). The allelic effect (OR)
increased when these EA cases were compared to 3491 EA
controls (P = 8.4361025, OR = 2.07, 95%CI = 1.42–2.99;
PTPN22 in Systemic Lupus Erythematosus
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FDR = 0.0008). The effect was further increased using 56 EA
patients with high titer aCL IgG.40 (P = 9.6761026, OR = 2.79
95%CI 1.73–4.48; FDR = 9.6761025). The MAF of the ‘A’ allele
increased from 8% in controls to 11% in all SLE cases, 15% in
cases positive for aCL IgG, and 20% in cases with aCL IgG.40.
Additional analyses suggest a positive correlation between risk
Figure 1. The haplotype structure of select SNPs from the PTPN22 region in EA controls. Blocks connecting SNP pairs are shaded
according to the strength of the linkage disequilibrium (r2).
doi:10.1371/journal.pone.0069404.g001
Table 1. Distribution of the minor allele frequency, case control association, and imputation-based association results for
significantly associated SNPs in European-Americans, Hispanic, African-Americans, and Asians.
EA (3936/3491) HS (1492/807) AA (1527/1811) AS (1265/1260)
SNP BP A typed F_A F_U P-val.
OR
(95%
CI) F_A F_U P-val.
OR
(95%
CI) F_A F_U P-val.
OR
(95%
CI) F_A F_U P-val.
OR
(95%
CI)
rs2476601 114179091 A/G genotyped 0.109 0.080 4.13E-9 1.40
(1.25–
1.56)
0.054 0.045 0.1988 1.20
(0.91–
1.60)
– – – – – – – –
rs3765598 114214190 T/C genotyped 0.188 0.186 0.7371 1.01
(0.93–
1.10)
0.138 0.168 0.0066 0.79
(0.67–
0.94)
0.089 0.085 0.5033 1.06
(0.89–
1.26)
0.218 0.202 0.1683 1.10
(0.96–
1.26)
rs1217414 114195986 A/C genotyped 0.256 0.280 7.39E-4 0.88
(0.82–
0.95)
0.180 0.191 0.3637 0.93
(0.80–
1.09)
0.669 0.676 0.5460 0.97
(0.88–
1.08)
0.071 0.081 0.1710 0.86
(0.70–
1.07)
A1 = minor allele; F_A = minor allele frequency for SLE cases; F_U = minor allele frequency for controls.
doi:10.1371/journal.pone.0069404.t001
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allele ‘A’ and higher aCL IgG titer in 1251 available European
samples (cases or controls) when aCL IgG titer used as a
phenotype in quantitative analyses tests (qtl) (P = 0.009). More-
over, 42% of these aCL positive lupus patients are also diagnosed
with anti-phospholipid syndrome (APS) with sufficient evidence of
thrombosis (peripheral, cerebral, cardiac or pulmonary). We
observed similar results in our EA population; 50 lupus patients
with aCL-positive APS compared to healthy control (P = 0.003,
OR = 2.17, 95%CI = 1.26–3.74; FDR = 0.03). A similar trend was
observed in Hispanics but the number of samples was not sufficient
(data not shown). However, there was no association between
rs2476601 and the presence of lupus anticoagulant (LA) with
negative or low titer aCL (P = 0.09). While not statistically
significant, we observed an increase in the odds ratio in Europeans
for the presence of lupus nephritis, or anti-dsDNA antibodies (1.49
and 1.47 respectively) for rs2476601.
We also found that EA lupus patients with co-existent thyroid
disease strengthened the observed association result. The OR for
SNP rs2476601 was increased to OR = 2.07 (95%CI 1.44–2.99),
when 117 European cases with co-existent thyroid disease were
compared with 3491 European controls with a MAF of 15% in
cases in compare to 8% in controls (P = 6.3861025; FDR = 0.001).
Among these, only 24 (20%) had aCL IgG.20 and in a separate
analysis, lupus patients with co-existent thyroid disease and aCL
IgG,20 (93 patients) still shows similar increased risk (P = 0.001,
OR = 1.94 95%CI 1.27–2.95). In case-only analyses when these
cases were compared with 514 SLE patients with no history of
thyroid disease a similar trend was obtained (P = 0.02, OR = 1.60,
95%CI = 1.06–2.39).
Although rs2476601 was not significantly associated with SLE
(P = 0.20) in HS, this SNP was marginally significant with anti-
nRNP positive SLE cases (P = 0.037, OR = 1.99; 108 cases
positive, 229 cases negative) in case-only analysis (Table 2). For
anti-nRNP positive cases versus healthy controls association
remained significant (P = 0.002, OR = 1.90). MAF of the ‘A’ allele
increased from 4.6% in controls to 8.3% in anti-nRNP positive
cases. SNP rs3765598 was associated with malar rash (P = 0.003,
OR = 1.91; 316 cases positive, 169 cases negative) but this result
was not confirmed in case positive vs. controls (P = 0.61,
OR = 0.95). While neither of the case-only results were significant
after adjusting for FDR (PnRNP-rs2476601 = 0.88, Pmalar-rs3765598 =
0.68), the sample sizes for these analyses were quite small
and lacked statistical power. Notable, SLE cases negative for
malar rash had the lowest MAF (MAFCONTROL = 16.8%,
MAFNEG = 8.6%, MAFPOS = 15.2).
We assessed (a) whether MAF is correlated with individual
European admixture, and (b) the impact of European admixture in
association. We only included EA and HS for this analysis since
these populations were polymorphic for this SNP. Indeed, MAF
increased for the rs2476601 risk allele (A) as the proportion of
European Admixture increased (Figure 2). Next, individuals were
grouped by European admixture proportion and allelic association
was performed for each group. For individuals with low
proportions of European admixture (below 40%; 157 cases and
132 controls) and those with moderate proportions of European
admixture (40–90%; 662 cases and 380 controls) rs2476601 was
not associated with SLE, Plow = 0.60 and Pmoderate = 0.10 respec-
tively. For individuals with the highest proportion of European
admixture (.90%; 3648 cases and 3450 controls) this SNP was
significantly associated with SLE (Phigh = 4.84610
29). Similar
results were found for rs1217414 (Plow = 0.40, Pmoderate = 0.78,
Phigh = 0.007).
We also performed this analysis based on proportion of Native
American ancestry. Individuals with low (,10%; 3870 cases and
3572 controls) or moderate proportion (10–30%; 255 cases and
131 controls) of Native American ancestry did not show SLE
association with rs3765598, Plow = 0.70 and Pmoderate = 0.99
respectively. However, individuals with relatively higher propor-
tions of Native American ancestry (.30%; 342 cases and 259
controls) did show significant association with SLE (Phigh = 0.018),
despite the relatively small sample size.
Discussion
We genotyped ten SNPs in PTPN22, including two missense
(rs2476601 (R620W), rs33996649 (R263Q)) and 59-UTR
(rs2488457) SNPs, in four large multi-ethnic populations.
Using these genotypes and HapMap data we imputed 107
SNPs in diverse ethnic groups to elucidate the effect size and
potential relation of these variants with SLE risk across
populations. Our results were consistent with previous reports:
we reinforced that SLE-association with PTPN22 is largely
accounted for by rs2476601 in individuals of European
ancestry [1,48,49,50]. While there is a strong North-South
gradient of the risk allele frequency across Europe [26], we
did not have sufficient AIMs determine North vs. South
European ancestry we could not assess the effect of this
gradient in our study. We were unable to detect association
with rs2476601 in AA or AS, or any other SNP within
PTPN22. This result is consistent with earlier reports that this
Table 2. Clinical criteria sub-analysis results for European-Americans and Hispanics.
case-only case positive-control
Population Criteria SNP A1 A2
#
pos #neg # ctrl F_P F_N F_U P-value FDR
OR (95%
CI) P-value FDR
OR (95%
CI)
EA aCL IgG rs2476601 A G 121 578 3491 0.156 0.100 0.080 0.0120 0.0492 1.65
(1.11–
2.46)
2.69E-5 2.23E-3 2.11
(1.48–
3.02)
HS anti-nRNP rs2476601 A G 108 229 807 0.083 0.044 0.045 0.0372 0.8763 1.99
(1.03–
3.85)
0.0019 0.9671 1.90
(1.07–
3.37)
HS malar rash rs3765598 T C 316 169 807 0.152 0.086 0.168 0.0034 0.6823 1.91
(1.23–
2.96)
0.6136 0.0770 0.95
(0.73–
1.25)
F_P = frequency for SLE cases positive for sub-criteria, F_N = frequency for SLE cases negative for sub-criteria, F_U = frequency for controls.
doi:10.1371/journal.pone.0069404.t002
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SNP is rare and not associated with SLE in AA [3,51] or in
Han Chinese [52].
Recent reports continue to shed light on mechanisms of non-
synonymous rs2476601 (R620W). PTPN22 encodes the protein
tyrosine phosphotase which has an important regulatory role in
multiple signaling pathways and functions to dephosphorylate
specific tyrosine residues in target proteins. The R620W mutation
changes the highly conserved amino acid arginine to tryptophan
which disrupts the P1 proline-rich motif and could cause
accelerated degradation of the tyrosine phosphotase protein
[53,54]. TCR signaling has been shown to be reduced in T cells
containing the disease-susceptibility allele [17]. Protein degrada-
tion may lead to hyper-responsiveness of lymphocyte and dendritic
cells, which could help explain increased risk for autoimmunity
[54]. Additionally, the PTPN22 risk genotype (R620W) may also
alter B cell signaling transduction either through decreases in B
cell proliferation or a deficit in phosphorylation of key signaling
proteins [20]. Recent murine studies provide important new
insight regarding the role of PTPN22 (R620W) risk allele in
regulation of signal transduction and maintenance of immune
tolerance. Interestingly, when the analog mutation of (R620W) has
been knocked into the murine ortholog of the gene, this mutation
did not influence the half-life of PTPN22 protein as previously
suggested [54] but altered receptor-mediated protein tyrosine
phosphorylation and caused hypersensitivity to antigen receptor
stimulation. Indeed, B cell expression of the risk variant was
sufficient to promote systemic autoimmunity [55,56].
After controlling for rs2476601 using conditional haplotype
analysis we found that it accounted for most of the association in
PTPN22. However, even after conditioning on rs2476601 there
was a modest association of rs1217414 with SLE. rs1217414 has
been implicated in early onset psoriasis [57] and RA [58,59] and
may be involved in autoimmunity predisposition. Additionally,
bioinfomatic search found that this SNP is potentially in an active
Figure 2. Minor allele frequency of rs2476601 and rs1217414 as a function of proportion of European admixture for SLE cases and
healthy controls.
doi:10.1371/journal.pone.0069404.g002
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promoter site for a chromatin regulatory site for B-lymphocyte
cells [54].
While non-synonymous rs33996649 (R263Q) did not pass the
threshold for significance, the P-value was suggestive (P = 0.08) in
EA. This SNP, which lies within the catalytic domain of enzyme, is
correlated with PTPN22 gene expression [60], leads to reduced
phosphatase activity [61] and was negatively associated with SLE
in Europeans [61]. An association independent of rs2476601 was
identified for rs1217414 and rheumatoid arthritis in populations of
European and Asian descent. Our data does not support a
significant association of this SNP with SLE in non-European
derived populations (Table S1).
In HS we observed association of potential eQTL rs3765598
with SLE. This SNP is in a potential enhancer of regulatory
chromatin site for CD4+CD252CD45RO+ memory primary
cells. Although the minor allele for rs3765598 is less common in
Yorubans (MAF = 4%), and is more common in individuals of
European descent (CEU MAF = 23%), it was not associated in our
EA population (P = 0.75).
We confirmed associations between PTPN22 SNPs with selected
autoantibody sub-phenotypes and with malar rash in indepen-
dently associated SNPs. We avoided inter-laboratory variation by
only considering data from OMRF testing laboratory. When
analyzing subgroups of SLE cases based upon clinical criteria,
there is usually a loss of power due to the smaller sample size
relative to all SLE. Alternatively, we can increase statistical power
by analyzing more homogenous groups when clinical phenotype is
more strongly associated compared to SLE. Because of these issues
using P-values alone is unreliable; therefore we look for an
increasing magnitude of the OR. In this report EA patients
positive for IgG anti-cardiolipin antibodies (aCL IgG) were
enriched for the risk allele (A) and effect sizes increased
(OR = 1.30 for SLE cases vs. controls, OR = 1.62 for case-only).
This was especially true for those with moderate to high
anticardiolipin antibodies (aCL IgG.40) as well as a subset of
APS patients who also were aCL positive (see above). This effect
was not detected in patients with low titer aCL or presence of only
lupus anticoagulant. ACL antibodies can be found in patients with
a wide spectrum of clinical conditions however the higher titers of
these antibodies are more commonly seen in APS. To our
knowledge the potential association of this SNP among patients
with primary or secondary APS has not been reported previously.
A recent study in a Polish population with endometriosis, only
those with positive anti-cardiolipin antibodies and anti-nuclear
antibodies were associated with rs2476601 (P = 0.009). However,
the number of samples was small and it is not clear whether any of
these patients suffered from co-existent APS [62]. It has been
reported in multiple lupus studies [63,64] that the presence of aCL
(IgG) antibodies in lupus patients especially those with APS
syndrome, are associated with poor prognosis, increased mortality,
and an earlier time of onset of several criteria, in particular malar
rash and nephritis. This could be related to thrombotic events in
kidney, vasculitis, arterial occlusions and coexistent thrombocyto-
penia. Given the notable increase of OR between general SLE
(ORSLE = 1.40) and SLE patients with APS (OR = 2.17),
rs2476601 could be a surrogate of lupus severity at least in
European ancestry. It is noteworthy that although availability of
data for specific autoantibodies, in particular aCL, were limited in
our cohorts, there was no evidence of heterogeneity or inconsis-
tency in risk ratio estimates between cohorts or any evidence of
site-specific confounding effect. Further studies are necessary to
confirm or refute this possibility.
In summary, in accordance with previous studies, our data on
multiethnic populations further confirmed that rs2476601
(R620W) is unequivocally associated with SLE in individuals with
European ancestry. Additionally, since rs2476601 was associat-
ed with aCL IgG our data suggests that this PTPN22 variant
might be associated with pathogenesis of antiphospholipid
syndrome in Europeans. We also detected significant association
with rs3765598 in HS, though no significant associations were
observed in AA or AS. Further, independent replication studies
are required in these populations to establish these novel
associations with SLE and its clinical sub-phenotypes and
autoantibody status.
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